Memory Impairment and Plasma BDNF Correlates of the BDNF Val66Met Polymorphism in Patients With Bipolar II Disorder

Yun-Hsuan Chang,Chih-Chun Huang,Jau-Shyong Hong,Po See Chen,Yen Kuang Yang,Sheng-Yu Lee,Ru-Band Lu,Shiou-Lan Chen,Tzu-Yun Wang

doi:10.3389/fgene.2018.00583

Abstract

Studies suggest that a functional polymorphism of brain-derived neurotrophic factor (BDNF), polymorphism BDNF Val66Met affects cognitive functions, however, the effect is unclear in bipolar II (BD-II) disorder. We used the Wechsler Memory Scale-third edition (WMS-III), the presence of the BDNF Val66Met polymorphism, and plasma concentrations of BDNF to investigate the association between memory impairment and BDNF in BD-II disorder. We assessed the memory functions of 228 BD-II patients and 135 healthy controls (HCs). BD-II patients had significantly lower scores on five of the eight WMS-III subscales. In addition to education, the BDNF polymorphism were associated with the following subscales of WMS-III, auditory delayed memory, auditory delayed recognition memory and general memory scores in BD-II patients, but not in HC. Moreover, BD-II patients with the Val-homozygote scored significantly higher on the visual immediate memory subscale than did those with the Met/Met and Val/Met polymorphisms. The significantly positive effect of the Val-homozygote did not have a significantly positive effect on memory in the HC group, however. We found no significant association between BDNF polymorphisms and plasma concentrations of BDNF. The plasma BDNF was more likely to be associated with clinical characteristics than it was with memory indices in the BD-II group. The impaired memory function in BD-II patients might be dependent upon the association between the BDNF Val66Met polymorphism and peripheral BDNF levels.

Highlights

Patients with bipolar disorder (BD) have a variety of cognitive deficits (Bearden et al, 2001; Murphy and Sahakian, 2001; Quraishi and Frangou, 2002) that might affect drug adherence, therapeutic outcomes, and prognosis (Simonsen et al, 2008)
Plasma concentrations of brain-derived neurotrophic factor (BDNF) were significantly higher in the healthy controls (HCs) group than in the BD-II group (F = 3.94, p = 0.04)
To explore which clinical characteristics and demographic variables are associated with plasma concentrations of BDNF, demographic data, age and gender, clinical characteristics, Hamilton Depression Rating Scale (HDRS) score, Young Mania Rating Scale (YMRS) score, age at onset of BD-II, and duration of illness were independent variables in the multivariate linear regression analyses, and plasma concentrations of BDNF were dependent variables

Summary

Introduction

Patients with bipolar disorder (BD) have a variety of cognitive deficits (Bearden et al, 2001; Murphy and Sahakian, 2001; Quraishi and Frangou, 2002) that might affect drug adherence, therapeutic outcomes, and prognosis (Simonsen et al, 2008). Most prior studies focused on patients with bipolar I disorder (BD-I) (Dickerson F. et al, 2004; Dickerson F.B. et al, 2004; Jamrozinski et al, 2009). Bipolar II disorder (BD-II) patients have a more chronic course with depressive episodes and shorter periods in remission than do BD-I patients (Judd et al, 2003). BD patients had significantly poorer executive function and memory that was more impaired than did healthy controls during remission (Martinez-Aran et al, 2004). This high correlation between poor memory and learning might explain the daily dysfunction in BD patients during remission

Methods

Results

Discussion

Conclusion